Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis

NCT03129126 is registered in ClinicalTrials.gov with Lipella Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03129126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03129126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
Lead sponsor
Lipella Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2020
Completion date
September 29, 2023
Enrollment
13 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhagic cystitis